FrancophonIA/ELRC3.0 huggingface dataset:
English: Other medically significant sequelae of overdose include delirium, convulsion, coma, possible neuroleptic malignant syndrome, respiratory depression, aspiration, hypertension or hypotension, cardiac arrhythmias (< 2 % of overdose cases) and cardiopulmonary arrest.
Croatian: Druge medicinski značajne posljedice predoziranja uključuju delirij, konvulzije, komu, mogući neuroleptički maligni sindrom, respiratornu depresiju, aspiraciju, hipertenziju ili hipotenziju, srčane aritmije (< 2% slučajeva predoziranja) i kardiopulmonalni arest.
English: Tardive dyskinesia11 Amnesia 9
Croatian: distonija (uključujući okulogiraciju)11 tardivna diskinezija11 amnezija9 dizartrija mucanje11, 13
English: • Tell the doctor if you or someone else in your family has a history of blood clots, as medicines like these have been associated with the formation of blood clots.
Croatian: • Obavijestite svog liječnika ako ste Vi ili netko drugi u Vašoj obitelji ranije imali krvne ugruške,
English: There was a 3-fold increase in CVAE in patients treated with olanzapine compared to patients treated with placebo (1.3% vs. 0.4%, respectively).
Croatian: U bolesnika liječenih olanzapinom zabilježen je trostruki porast CV štetnih događaja u usporedbi s bolesnicima koji su primali placebo (1,3% naspram 0,4%).
English: Olanzapine for injection should not be combined in a syringe with diazepam injection because precipitation occurs when these products are mixed.
Croatian: Olanzapin za injekcije ne smije se miješati u štrcaljki s diazepamom za injekcije jer pri miješanju ovih dvaju lijekova dolazi do precipitacije.
English: In a second 12-month recurrence prevention study in manic episode patients who achieved remission with a combination of olanzapine and lithium and were then randomised to olanzapine or lithium alone, olanzapine was statistically non-inferior to lithium on the primary endpoint of bipolar recurrence (olanzapine 30.0%, lithium 38.3%; p = 0.055).
Croatian: U drugom 12-mjesečnom ispitivanju prevencije relapsa epizode manije, bolesnici koji su postigli remisiju kombinacijom olanzapina i litija te su potom bili randomizirani u skupinu koja je primala samo olanzapin ili samo litij, olanzapin nije bio statistički inferioran litiju u pogledu primarne mjere ishoda - relapsa bipolarnog poremećaja (olanzapin 30,0%, litij 38,3%; p=0,055).
English: ZYPREXA 2.5 mg coated tablets ZYPREXA 5 mg coated tablets ZYPREXA 7.5 mg coated tablets ZYPREXA 10 mg coated tablets ZYPREXA 15 mg coated tablets ZYPREXA 20 mg coated tablets Olanzapine
Croatian: ZYPREXA 2,5 mg obložene tablete ZYPREXA 5 mg obložene tablete ZYPREXA 7,5 mg obložene tablete ZYPREXA 10 mg obložene tablete ZYPREXA 15 mg obložene tablete ZYPREXA 20 mg obložene tablete olanzapin
English: • High blood sugar and high levels of fat (triglycerides and cholesterol) have been seen in patients taking ZYPREXA.
Croatian: • U bolesnika koji uzimaju lijek ZYPREXA uočena je visoka razina šećera i masnoća u krvi (trigliceridi i kolesterol).
English: ZYPREXA 2.5 mg coated tablets ZYPREXA 5 mg coated tablets ZYPREXA 7.5 mg coated tablets ZYPREXA 10 mg coated tablets ZYPREXA 15 mg coated tablets ZYPREXA 20 mg coated tablets
Croatian: ZYPREXA 2,5 mg obložene tablete ZYPREXA 5 mg obložene tablete ZYPREXA 7,5 mg obložene tablete ZYPREXA 10 mg obložene tablete ZYPREXA 15 mg obložene tablete ZYPREXA 20 mg obložene tablete
English: Package leaflet: Information for the user ZYPREXA 10 mg powder for solution for injection Olanzapine
Croatian: Uputa o lijeku: Informacije za korisnika ZYPREXA 10 mg prašak za otopinu za injekciju olanzapin
English: ZYPREXA contains lactose
Croatian: ZYPREXA sadrži laktozu
English: The undesirable effects listed below have been observed following administration of oral and prolonged release intramuscular injection olanzapine, but may also occur following administration of ZYPREXA powder for solution for injection.
Croatian: Nuspojave navedene u nastavku primijećene su nakon primjene oralnog olanzapina, ali se mogu javiti i nakon primjene ZYPREXA praška za otopinu za injekciju.
English: After reconstitution each ml of the solution contains 5 mg olanzapine.
Croatian: Nakon rekonstitucije jedan ml otopine sadrži 5 mg olanzapina.
English: Withdraw 2.1 ml of water for injection into a sterile syringe.
Croatian: Uvucite 2,1 ml vode za injekcije u sterilnu štrcaljku i injicirajte je u bočicu ZYPREXA praška.
English: The most frequently (seen in ≥ 1% of patients) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism, leukopenia, neutropenia (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic aminotransferases (see section 4.4), rash, asthenia, fatigue, pyrexia, arthralgia, increased alkaline phosphatase, high gamma glutamyltransferase, high uric acid, high creatine phosphokinase and oedema.
Croatian: Najčešće prijavljene nuspojave (uočene u ≥ 1% bolesnika) povezane s primjenom olanzapina u kliničkim ispitivanjima bile su somnolencija, povećanje tjelesne težine, eozinofilija, povišene vrijednosti prolaktina, kolesterola, glukoze i triglicerida (vidjeti dio 4.4), glikozurija, povećan apetit, omaglica, akatizija, parkinsonizam, leukopenija, neutropenija (vidjeti dio 4.4), diskinezija, ortostatska hipotenzija, antikolinergički učinci, prolazni asimptomatski porasti vrijednosti jetrenih aminotransferaza (vidjeti dio 4.4), osip, astenija, umor, pireksija, artralgija, povišena razina alkalne fosfataze, visoka razina gama glutamiltransferaze, visoka razina mokraćne kiseline, visoka razina kreatin fosfokinaze i edem.
English: The most frequently (seen in ≥ 1 % of patients) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism, leukopenia, neutropenia (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic aminotransferases (see section 4.4), rash, asthenia, fatigue, pyrexia, arthralgia, increased alkaline phosphatase, high gamma glutamyltransferase, high uric acid, high creatine phosphokinase and oedema.
Croatian: Najčešće prijavljene nuspojave (uočene u ≥ 1% bolesnika) povezane s primjenom olanzapina u kliničkim ispitivanjima bile su somnolencija, povećanje tjelesne težine, eozinofilija, povišene vrijednosti prolaktina, kolesterola, glukoze i triglicerida (vidjeti dio 4.4), glikozurija, povećan apetit, omaglica, akatizija,parkinsonizam, leukopenija, neutropenija (vidjeti dio 4.4), diskinezija, ortostatska hipotenzija, antikolinergički učinci, prolazni asimptomatski porasti vrijednosti jetrenih aminotransferaza (vidjeti dio 4.4), osip, astenija, umor, pireksija, artralgija, povišena razina alkalne fosfataze, visoka razina gama glutamiltransferaze, visoka razina mokraćne kiseline, visoka razina kreatin fosfokinaze i edem.
English: If your doctor has to give a benzodiazepine injection to treat your condition, there should be at least a one hour time period after the ZYPREXA injection and you are to be monitored closely after the benzodiazepine injection is given.
Croatian: Ako Vam liječnik mora dati injekciju benzodiazepina za liječenje bolesti, mora pričekati da prođe najmanje jedan sat nakon injekcije lijeka
English: Additional injections, when indicated, should be conservative in such patients.
Croatian: treba biti konzervativna u takvih bolesnika.
English: LIST OF EXCIPIENTS Lactose monohydrate, tartaric acid, hydrochloric acid, sodium hydroxide
Croatian: Laktoza hidrat, tartaratna kiselina, kloridna kiselina, natrijev hidroksid.
English: Your doctor or nurse will make it up into a solution.
Croatian: Liječnik ili medicinska sestra će
English: Keep this medicine out of the sight and reach of children.
Croatian: Kako čuvati lijek ZYPREXA Lijek čuvajte izvan pogleda i dohvata djece.
English: Your doctor should do blood tests to check blood sugar and certain fat levels before you start taking ZYPREXA and regularly during treatment.
Croatian: Prije početka uzimanja lijeka ZYPREXA te redovito tijekom liječenja, liječnik bi Vam trebao obaviti krvne pretrage kako bi provjerio razinu šećera i određenih masnoća u krvi.
English: Crospovidone Microcrystalline cellulose Magnesium stearate
Croatian: Jezgra tablete laktoza hidrat hiproloza krospovidon celuloza, mikrokristalična magnezijev stearat
English: ZYPREXA 20 mg coated tablets are pink.
Croatian: ZYPREXA 20 mg obložene tablete su ružičaste.
English: In comparator oral studies of one year or less duration, olanzapine was associated with a statistically significant lower incidence of treatment emergent dyskinesia.
Croatian: Tardivna diskinezija U ispitivanjima usporednih skupina u trajanju do godinu dana ili kraće, olanzapin je bio povezan sa statistički značajno nižom incidencijom diskinezije koja se javlja s liječenjem.
English: ZYPREXA contains the active substance olanzapine.
Croatian: Što je ZYPREXA i za što se koristi ZYPREXA sadrži djelatnu tvar olanzapin.
English: Do not store above 25º C. Do not freeze.
Croatian: Ne čuvati na temperaturi iznad 25ºC.
English: Patients gaining ≥ 7 %, ≥ 15 % and ≥ 25 % of their baseline body weight with long-term exposure (at least 48 weeks) were very common (64.4 %, 31.7 % and 12.3 % respectively).
Croatian: Tijekom dugotrajne izloženosti lijeku (najmanje 48 tjedana) povećanje tjelesne težine ≥ 7%, ≥ 15% i ≥ 25% od početne bilo je vrlo često (64,4%, 31,7%, odnosno
English: What you need to know before you are given ZYPREXA
Croatian: Što morate znati prije nego počnete primati lijek ZYPREXA
English: Name and address of the manufacturer(s) responsible for batch release
Croatian: PROIZVOĐAČI ODGOVORNI ZA PUŠTANJE SERIJE LIJEKA U PROMET Naziv i adresa proizvođača odgovornih za puštanje serije lijeka u promet
English: 1 vial EU/1/96/022/017 Powder for solution for injection.
Croatian: 1 bočica EU/1/96/022/017 Prašak za otopinu za injekciju.
English: (See sections 4.5 and 5.2)
Croatian: (vidjeti dio 4.6)
English: What ZYPREXA looks like and contents of the pack ZYPREXA 2.5 mg coated tablets are white imprinted with “LILLY” and a numeric identicode “4112”.
Croatian: Kako ZYPREXA izgleda i sadržaj pakiranja ZYPREXA 2,5 mg obložene tablete su bijele s otisnutom oznakom “LILLY” i brojčanom identifikacijskom oznakom “4112”.
English: NAME OF THE MEDICINAL PRODUCT ZYPREXA 10 mg powder for solution for injection
Croatian: NAZIV LIJEKA ZYPREXA 10 mg prašak za otopinu za injekciju
English: Gastrointestinal disorders Mild, transient anticholinergic effects including constipation and dry mouth
Croatian: Poremećaji probavnog sustava blagi, prolazni antikolinergički učinci uključujući konstipaciju i suha usta distenzija abdomena9
English: In female versus male subjects administered oral olanzapine the mean elimination half life was somewhat prolonged (36.7 versus 32.3 hrs) and the clearance was reduced (18.9 versus 27.3 l/hr).
Croatian: U žena koje su primile oralni olanzapin je prosječno poluvrijeme eliminacije bilo nešto duže u odnosu na muškarce (36,7 naspram 32,3 sata), a klirens je bio smanjen (18,9 naspram 27,3 l/h).
English: Other symptoms may be: acute confusion, seizures (epilepsy), coma, a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness, slowing of the breathing rate, aspiration, high blood pressure or low blood pressure, abnormal rhythms of the heart.
Croatian: kombinacija vrućice, ubrzanog disanja, znojenja, ukočenosti mišića i omamljenosti ili pospanosti, usporavanje disanja, aspiracija, visok krvni tlak ili nizak krvni tlak, poremećaj srčanog ritma.
English: TABLET STRENGTH
Croatian: Ovojnica tablete
English: 1 mg olanzapine is retained in the vial and syringe, thus allowing delivery of 10mg olanzapine.
Croatian: Ako se izvuče 2,0 ml otopine, u bočici i štrcaljki preostaje 1 mg olanzapina, čime se omogućuje primjena 10 mg olanzapina.
English: In a multinational, double-blind, comparative study of schizophrenia, schizoaffective, and related disorders which included 1,481 patients with varying degrees of associated depressive symptoms (baseline mean of 16.6 on the Montgomery-Asberg Depression Rating Scale), a prospective secondary analysis of baseline to endpoint mood score change demonstrated a statistically significant improvement (p= 0.001) favouring olanzapine (-6.0) versus haloperidol (-3.1).
Croatian: U multinacionalnom, dvostruko slijepom, komparativnom ispitivanju shizofrenije, shizoafektivnih i povezanih poremećaja, koje je obuhvaćalo 1481 bolesnika s različitim stupnjevima pridruženih simptoma depresije (srednja početna vrijednost 16,6 po Montgomery-Asberg ljestvici depresije),
English: How to take ZYPREXA
Croatian: Kako uzimati lijek ZYPREXA
English: METHOD AND ROUTE(S) OF ADMINISTRATION Intramuscular use.
Croatian: NAČIN I PUT(EVI) PRIMJENE LIJEKA Za intramuskularnu primjenu.
English: In renally impaired patients (creatinine clearance < 10 ml/min) versus healthy subjects, there was no significant difference in mean elimination half-life (37.7 versus 32.4 hr) or clearance (21.2 versus 25.0 l/hr).
Croatian: U bolesnika s oštećenjem bubrega (klirens kreatinina < 10 ml/min) nije bilo značajne razlike u odnosu na zdrave ispitanike u prosječnom poluvremenu eliminacije (37,7 naspram 32,4 sata) ili klirensu
English: ZYPREXA 20 mg tablets
Croatian: ZYPREXA 20 mg tablete
English: 13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) was very common (40.6 %), ≥ 15 % of baseline body weight was common (7.1 %) and ≥ 25 % was common (2.5 %).
Croatian: 13 Nakon kratkotrajnog liječenja (medijan trajanja 22 dana), povećanje tjelesne težine ≥ 7% od početne tjelesne težine (kg) bilo je vrlo često (40,6%), porast ≥ 15% od početne tjelesne težine bio je čest
English: ZYPREXA coated tablets are for oral use.
Croatian: ZYPREXA obložene tablete uzimaju se kroz usta.
English: Thus no particular interaction is expected as verified through in vivo studies where no inhibition of metabolism of the following active substances was found: tricyclic antidepressant (representing mostly CYP2D6 pathway), warfarin (CYP2C9), theophylline (CYP1A2) or diazepam (CYP3A4 and 2C19).
Croatian: Stoga se ne očekuje nikakva posebna interakcija, što potvrđuju in vivo ispitivanja u kojima nije nađena inhibicija metabolizma sljedećih djelatnih tvari: tricikličkih antidepresiva (predstavljaju glavninu
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON OF VIAL OF POWDER
Croatian: PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU
English: If you suffer from dementia, you or your carer/relative should tell your doctor if you have ever had a stroke or “mini” stroke.
Croatian: Ako bolujete od zaboravljivosti (demencije), a imali ste moždani udar ili “manji” moždani udar, Vi ili
English: Administer the solution intramuscularly.
Croatian: Primijenite otopinu intramuskularno.
English: < 6.2 mmol/l) to high (≥ 6.2 mmol/l) were very common.
Croatian: (≥ 5,17-< 6,2 mmol/l) do visokih vrijednosti (≥ 6,2 mmol/l) bile su vrlo česte.
English: INFORMATION IN BRAILLE ZYPREXA 20 mg
Croatian: 16. PODACI NA BRAILLEOVOM PISMU ZYPREXA 20 mg
English: INFORMATION IN BRAILLE ZYPREXA 7.5 mg
Croatian: 16. PODACI NA BRAILLEOVOM PISMU ZYPREXA 7,5 mg
English: In non-smoking versus smoking subjects (males and females) administered olanzapine intramuscularly the mean elimination half-life was prolonged (38.6 versus 30.4 hr) and the clearance was reduced (18.6 versus 27.7 l/hr).
Croatian: U nepušača u usporedbi s pušačima (muškarcima i ženama), u kojih je olanzapin primijenjen intramuskularno, srednje poluvrijeme eliminacije bilo je produljeno (38,6 naspram 30,4 h), a klirens smanjen (18,6 naspram 27,1 l/h).
English: Powder for Solution for Injection
Croatian: Prašak za otopinu za injekciju
English: In healthy elderly (65 and over) versus non-elderly subjects administered oral olanzapine, the mean elimination half-life was prolonged (51.8 versus 33.8 hr) and the clearance was reduced (17.5 versus 18.2 l/hr).
Croatian: U zdravih starijih ispitanika (65 godina i starijih) u odnosu na mlađe ispitanike koji su primili oralni olanzapin prosječno poluvrijeme eliminacije bilo je produljeno (51,8 naspram 33,8 sati), a klirens smanjen (17,5 naspram 18,2 l/h).
English: Colour mixture light blue (titanium dioxide E171, lactose monohydrate, hypromellose, triacetin, indigo carmine colour (E132))
Croatian: ZYPREXA 15 mg obložene tablete hipromeloza mješavina svjetloplave boje (titanijev dioksid (E171), laktoza hidrat, hipromeloza, triacetin, boja indigo karmin (E132)) karnauba vosak
English: ZYPREXA 15 mg tablets
Croatian: ZYPREXA 15 mg tablete
English: If you suddenly stop taking ZYPREXA, symptoms such as sweating, unable to sleep, tremor, anxiety or nausea and vomiting might occur.
Croatian: Ako naglo prestanete s uzimanjem lijeka ZYPREXA mogu se pojaviti simptomi poput znojenja,
English: How to store ZYPREXA
Croatian: Kako čuvati lijek ZYPREXA
English: Colour mixture pink (titanium dioxide E171, macrogol, lactose monohydrate, hypromellose, synthetic red iron oxide)
Croatian: ZYPREXA 20 mg obložene tablete hipromeloza mješavina ružičaste boje (titanijev dioksid (E171), makrogol, laktoza hidrat, hipromeloza, sintetski željezov oksid, crveni) karnauba vosak
English: 4.9 Overdose
Croatian: 4.9 Predoziranje Znakovi i simptomi
English: ZYPREXA 7.5 mg coated tablets
Croatian: ZYPREXA 7,5 mg obložene tablete
English: Information on reconstitution and administration is provided in a detachable section at the end of this leaflet.
Croatian: Kako ćete primati lijek ZYPREXA Informacije o pripremi za primjenu i primjeni nalaze se u odvojivom dijelu na kraju ove upute.
English: ZYPREXA 20 mg coated tablets Pink, elliptical, coated tablets debossed with “LILLY” and a numeric identicode, “4420”.
Croatian: Ružičaste, eliptične, obložene tablete s otisnutom oznakom “LILLY” i brojčanom identifikacijskom oznakom “4420”.
English: INFORMATION IN BRAILLE ZYPREXA 2.5 mg
Croatian: 16. PODACI NA BRAILLEOVOM PISMU ZYPREXA 2,5 mg
English: 1 vial Powder for solution for injection.
Croatian: 1 bočica Prašak za otopinu za injekciju.
English: (≥ 1.467 mmol/l) and changes in fasting triglycerides from borderline at baseline (≥ 1.016 mmol/l
Croatian: 14 Uočeno za normalne početne razine triglicerida natašte (< 1,016 mmol/l) koje su porasle na visoke razine (≥ 1,467 mmol/l) i promjene u vrijednosti triglicerida natašte od početnih graničnih vrijednosti (≥ 1,016 mmol/l-< 1,467 mmol/l) do visokih vrijednosti (≥ 1,467 mmol/l).
English: ZYPREXA comes as a powder.
Croatian: ZYPREXA dolazi u obliku žutog praška u bočici.
English: ZYPREXA 5 mg coated tablets are white imprinted with “LILLY” and a numeric identicode “4115”.
Croatian: ZYPREXA 5 mg obložene tablete su bijele s otisnutom oznakom “LILLY” i brojčanom identifikacijskom oznakom “4115”.
English: ZYPREXA 7.5 mg coated tablets are white imprinted with “LILLY” and a numeric identicode “4116”.
Croatian: ZYPREXA 7,5 mg obložene tablete su bijele s otisnutom oznakom “LILLY” i brojčanom identifikacijskom oznakom “4116”.
English: Lactose monohydrate Tartaric acid, E334
Croatian: 6.1 Popis pomoćnih tvari laktoza hidrat tartaratna kiselina, (E 334) kloridna kiselina natrijev hidroksid
English: Excipient with known effect: Each coated tablet contains 178 mg lactose monohydrate.
Croatian: Pomoćna tvar s poznatim učinkom: Jedna obložena tableta sadrži 178 mg laktoze hidrata.
English: ZYPREXA 10 mg coated tablets are white imprinted with “LILLY” and a numeric identicode “4117”.
Croatian: ZYPREXA 10 m obložene tablete su bijele s otisnutom oznakom “LILLY” i brojčanom identifikacijskom oznakom “4117”.
English: Excipient with known effect: Each coated tablet contains 156 mg lactose monohydrate.
Croatian: Pomoćna tvar s poznatim učinkom: Jedna obložena tableta sadrži 156 mg laktoze hidrata.
English: Powder for Solution for Injection.
Croatian: Prašak za otopinu za injekciju.
English: NAME OF THE MEDICINAL PRODUCT ZYPREXA 10 mg powder for solution for injection olanzapine
Croatian: ZYPREXA 10 mg prašak za otopinu za injekciju olanzapin
English: INFORMATION IN BRAILLE ZYPREXA 15 mg
Croatian: 16. PODACI NA BRAILLEOVOM PISMU ZYPREXA 15 mg
English: MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS ZYPREXA 7.5 mg COATED TABLETS: BLISTER FOIL LABEL
Croatian: PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP ZYPREXA 7,5 mg OBLOŽENE
English: Other uncommon side effects (may affect up to 1 in 100 people) include hypersensitivity (e.g. swelling in the mouth and throat, itching, rash): diabetes or the worsening of diabetes, occasionally associated with ketoacidosis (ketones in the blood and urine) or coma; seizures, usually associated with a history of seizures (epilepsy); muscle stiffness or spasms (including eye movements); restless legs syndrome; problems with speech; stuttering; slow heart rate; sensitivity to sunlight; bleeding from nose; abdominal distension; memory loss or forgetfulness; urinary incontinence; lack of ability to urinate; hair loss; absence or decrease in menstrual periods; and changes in breasts in males and females such as an abnormal production of breast milk or abnormal growth.
Croatian: Druge manje česte nuspojave (mogu se pojaviti u do 1 na 100 osoba) uključuju preosjetljivost (npr. oticanje u ustima i grlu, svrbež; osip); šećernu bolest ili pogoršanje šećerne bolesti, ponekad povezano s ketoacidozom (ketonima u krvi i mokraći) ili komom; napadaje, obično povezane s napadajima u povijesti bolesti (epilepsija); mišićnu ukočenost ili grč (uključujući pokrete očiju); sindrom nemirnih nogu; poteškoće s govorom; mucanje; osjetljivost na sunčevu svjetlost; krvarenje iz nosa; nadimanje trbuha; gubitak pamćenja ili zaboravljivost; nemogućnost zadržavanja mokraće (inkontinencija); nemogućnost mokrenja; ispadanje kose; izostanak ili smanjenje mjesečnice i promjene na grudima u muškaraca i žena, kao što je poremećaj stvaranja majčinog mlijeka ili abnormalan rast.
English: Uncommon side effects (may affect up to 1 in 100 people) include hypersensitivity (e.g. swelling in the mouth and throat, itching, rash); diabetes or the worsening of diabetes, occasionally associated with ketoacidosis (ketones in the blood and urine) or coma; seizures, usually associated with a history of seizures (epilepsy); muscle stiffness or spasms (including eye movements); restless legs syndrome; problems with speech; stuttering; slow heart rate; sensitivity to sunlight; bleeding from the nose; abdominal distension; memory loss or forgetfulness; urinary incontinence; lack of ability to urinate; hair loss; absence or decrease in menstrual periods; and changes in breasts in males and females such as an abnormal production of breast milk or abnormal growth.
Croatian: Manje česte nuspojave (mogu se pojaviti u do 1 na 100 osoba) uključuju preosjetljivost (npr. oticanje u ustima i grlu, svrbež; osip); šećernu bolest ili pogoršanje šećerne bolesti, ponekad povezano s ketoacidozom (ketonima u krvi i mokraći) ili komom; napadaje, obično povezane s napadajima u povijesti bolesti (epilepsija); mišićnu ukočenost ili grč (uključujući pokrete očiju); sindrom nemirnih nogu; poteškoće s govorom; mucanje; usporen rad srca; osjetljivost na sunčevu svjetlost; krvarenje iz nosa; nadimanje trbuha; gubitak pamćenja ili zaboravljivost; nemogućnost zadržavanja mokraće (inkontinencija); nemogućnost mokrenja; ispadanje kose; izostanak ili smanjenje mjesečnice i promjene na grudima u muškaraca i žena, kao što je poremećaj stvaranja majčinog mlijeka ili abnormalan rast.
English: Excipient with known effect: Each coated tablet contains 102 mg lactose monohydrate.
Croatian: Pomoćna tvar s poznatim učinkom: Jedna obložena tableta sadrži 102 mg laktoze hidrata.
English: ZYPREXA 2.5 mg coated tablets
Croatian: ZYPREXA 2,5 mg obložene tablete
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each coated tablet contains 7.5 mg olanzapine
Croatian: NAVOĐENJE DJELATNE(IH) TVARI Jedna obložena tableta sadrži 7,5 mg olanzapina.